Dramatic bone remodeling following larotrectinib administration for bone metastasis in a patient with TRK fusion congenital mesoblastic nephroma.
Pediatr Blood Cancer
; 65(10): e27271, 2018 10.
Article
em En
| MEDLINE
| ID: mdl-29893456
ABSTRACT
Mesoblastic nephroma is the most frequent renal tumor in newborns and young infants, and the cellular type is characterized by an ETV6-NTRK fusion, which constitutively activates the tropomyosin-related kinase (TRK) signaling pathway. Larotrectinib is a highly selective TRK inhibitor with activity in adult and pediatric patients who have TRK fusions. We present a rare case of a patient with mesoblastic nephroma metastatic to bone who had a dramatic response to larotrectinib.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Pirazóis
/
Pirimidinas
/
Neoplasias Ósseas
/
Remodelação Óssea
/
Nefroma Mesoblástico
/
Neoplasias Renais
/
Antineoplásicos
Limite:
Humans
/
Infant
/
Male
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article